Pharma sector boosts FTSE

Bid talk in the pharma sector has given the FTSE 100 a post-Easter bounce, with the index kicking off the shortened week with an initial gain of 50 points.

Traders have stumbled back to their desks this morning after an indulgent long weekend of chocolate consumption. Whilst the economic day has gotten off to a slow start, there has been bid activity that has seen the premier index rise to its highest level in around two weeks. Last week’s price action witnessed a significant turnaround in market direction, as earnings season provided indices with the positive momentum needed to halt what had looked to be a wave of selling. 

Reports in the weekend press suggested Pfizer had been interested in UK pharma giant AstraZeneca. The news has propelled AstraZeneca to the top of the leaderboard this morning, with sector peers GlaxoSmithKline and Shire following along in its wake. AstraZeneca briefly revisited £41 a share this morning, the highpoint of its recent rally, but since then the shares have dropped back. However, the development pipeline of drugs that would come with any acquisition of AstraZeneca means Pfizer may not be easily deterred. A purchase of AstraZeneca would make sense for Pfizer, given an overseas acquisition would avoid the need to repatriate assets back to the US.

The pace of earnings reports becomes frenetically busy this week, with many major names updating the market. However, the big events will be Facebook and Apple, as the tech giants look to recover from the momentum selloff we witnessed before Easter.

US indices have staged an impressive bounceback from the mid-April lows, with the Dow Jones seemingly back on course to retarget previous highs. Ahead of the open, we expect the Dow to start 18 points lower at 16,431, after yesterday’s modest gains. 

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.